Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. reports developments as a late-stage biopharmaceutical company focused on oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a liver-selective glucokinase activator being investigated as an oral adjunctive therapy to insulin for type 1 diabetes. Company updates also reference development work and partnerships across additional chronic-disease candidates, including the PDE4 inhibitor HPP737.
Recurring announcements include clinical and regulatory updates for cadisegliatin, financial results and corporate updates, license and collaboration activity, investor-conference participation, and Nasdaq inducement grants under equity compensation plans. News about vTv often connects pipeline progress with funding arrangements, intellectual property, and business-development agreements that support its drug-development strategy.
vTv Therapeutics Inc. (Nasdaq:VTVT) reported its Q2 2021 financial results, highlighting a net loss of $608,000, significantly improved from a $4.2 million loss in Q1 2021. Cash reserves increased to $10.8 million. The company held a productive FDA meeting regarding its Breakthrough Therapy designation for TTP399, planning two pivotal studies to commence in early 2022. Revenue for Q2 was minimal at $9, with $2.4 million in R&D expenses. vTv announced a $50 million ATM equity program to support ongoing developments.
vTv Therapeutics, a clinical-stage biopharmaceutical company, announced it will present clinical data on HPP737, an orally administered PDE4 inhibitor for psoriasis, at the 6th World Psoriasis & Psoriatic Arthritis Conference from June 30 to July 3, 2021. The poster, titled Pharmacokinetics and Pharmacodynamics of HPP737, will be presented by Aaron Burstein, PharmD. HPP737 has shown strong efficacy and safety in clinical trials, making it a promising treatment option for psoriasis. More details will be available on vTv's website post-presentation.
vTv Therapeutics has announced a licensing agreement with Cantex Pharmaceuticals, granting Cantex exclusive rights to develop and commercialize azeliragon, a drug aimed at treating complications associated with cancer. This phase 2-ready medication has shown a favorable safety profile in previous Alzheimer’s trials. Cantex plans to initiate clinical trials to explore azeliragon's potential. The collaboration allows both companies to share profits from the commercialization of the drug, promising a strategic partnership in addressing significant medical needs.
vTv Therapeutics (Nasdaq: VTVT) reported Q1 2021 financials, highlighting key developments in its diabetes treatment program. The FDA granted Breakthrough Therapy designation to TTP399, which aims to significantly improve treatment for type 1 diabetes. The company initiated two phase 1 clinical studies for TTP399 and HPP737, with topline results expected in Q3 2021. Financially, vTv reported $1.0 million in revenue and a net loss of $4.2 million, translating to a diluted loss of $0.08 per share. Cash reserves increased to $8.4 million, showing better liquidity compared to the previous quarter.
vTv Therapeutics Inc. (Nasdaq: VTVT) announced that the FDA has granted Breakthrough Therapy designation for TTP399, an oral investigational therapy for type 1 diabetes. This designation allows for expedited development and review, acknowledging TTP399's potential to significantly improve clinical outcomes. Positive results from the phase 2 SimpliciT-1 study highlighted a significant reduction in HbA1c and hypoglycemia events. This milestone addresses a serious medical need for over a million individuals affected by type 1 diabetes.
Summary not available.
vTv Therapeutics announced the issuance of the U.S. Patent 10,952,993, protecting treatment methods using TTP399 for type 1 diabetes. This patent, expiring in 2039, covers lowering HbA1c and reducing hypoglycemia incidence by administering 400 mg to 1200 mg of TTP399 daily alongside insulin. The company aims for Orange Book listing and is enhancing its patent portfolio. TTP399 is currently under study for diabetic ketoacidosis and is set for pivotal trials this year.
vTv Therapeutics (Nasdaq: VTVT) announced the start of a mechanistic phase 1 study to evaluate TTP399, a liver-selective glucokinase activator, in people with type 1 diabetes. This study focuses on the effects of TTP399 on ketone formation during insulin withdrawal, aiming to demonstrate that it does not increase ketone production, a precursor to ketoacidosis. Previous phase 2 studies showed TTP399 improved glycemic control without raising the risk of ketoacidosis or hypoglycemia. The company plans to initiate a pivotal study later this year.
vTv Therapeutics Inc. (Nasdaq: VTVT) announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled virtually for March 9-10, 2021. During the event, the company will offer a general update through an on-demand presentation starting March 9, and management will hold one-on-one virtual meetings with investors. vTv focuses on developing oral treatments for type 1 diabetes and inflammatory diseases, with a clinical pipeline that includes indications for other diseases such as type 2 diabetes and COPD.
vTv Therapeutics Inc. (Nasdaq: VTVT) reported its financial results for Q4 2020, showing a revenue of $6.4 million, driven primarily by a licensing agreement with Anteris Bio. The company transitioned from a net loss of $2.3 million in Q3 2020 to a net income of $1.6 million in Q4. The Phase 2 SimpliciT-1 study results for TTP399 were published, showing significant reductions in HbA1c for type 1 diabetes patients. The firm plans to initiate pivotal trials for TTP399 in H2 2021 and has a cash position of $5.7 million.